LI-COR IRDye® 800CW RGD 光学探头,LI-COR IRDye® 800CW RGD

Reagents > IRDye® 800CW RGD Optical Probe,IRDye® 800CW RGD 光学探头

IRDye® 800CW RGD Optical Probe

IRDye 800CW RGD Optical Probe is a BrightSite™ near-infrared (NIR) fluorescently-labeled RGD imaging agent specifically designed to target the overexpression of integrins on tumors.

Integrins are cell surface heterodimeric glycoproteins involved in cell-to-cell and cell-to-matrix interactions. IRDye 800CW RGD Optical Probe is composed of the recognition motif, RGD (Arg-Gly-Asp), a tripeptide sequence used to bind integrin receptors including αvβ3. This receptor class is involved in tumor growth, tumor invasiveness, metastasis, tumor induced angiogenesis, inflammation, osteoporosis, and rheumatoid arthritis.

Interest in using a labeled RGD peptide ligand for the study and/or monitoring of diseases related to the αvβ3 receptor over-expression is increasing. Several groups have labeled RGD successfully with fluorescent dyes for in vitro and in vivo imaging.

IRDye 800CW RGD 光学探头是一种 BrightSite™ 近红外 (NIR) 荧光标记的 RGD 显像剂，专门设计用于靶向肿瘤上整合素的过度表达。

整联蛋白是细胞表面异二聚体糖蛋白，参与细胞与细胞和细胞与基质的相互作用。 IRDye 800CW RGD 光学探针由识别基序 RGD (Arg-Gly-Asp) 组成，这是一个三肽序列，用于结合包括 αvβ3 在内的整联蛋白受体。 该受体类别涉及肿瘤生长、肿瘤侵袭性、转移、肿瘤诱导的血管生成、炎症、骨质疏松症和类风湿性关节炎。

使用标记的 RGD 肽配体研究和/或监测与 αvβ3 受体过度表达相关的疾病的兴趣正在增加。 几个小组已经成功地用荧光染料标记了 RGD，用于体外和体内成像。

Learn about other LI-COR optical probes.

Applications

  • Microscopy
  • Optical Probe Development
  • Target Specificity

Absorbance and Emission Spectra

IRDye® 800CW RGD Optical Probe

Data Example

IRDye® 800CW RGD Optical Probe
A) The On-Cell Western cell-based assay was used to evaluate binding affinity of IRDye 800CW RGD to U87 (glioblastoma) and 22Rv1 (prostate carcinoma) tumor cell lines. B) Binding of the IRDye 800CW RGD peptide was blocked by unlabeled RGD but not by a non-specific RAD peptide in U87 tumor cells. Nude mice bearing subcutaneous tumors, U87 (left hip) and A431(right hip), were imaged 24 hours post intravenous injection of IRDye 800CW RGD (1 nmole; C) or IRDye 800CW RGD (1 nmole) following a pre-injection 1 hour prior to an injection of unlabeled RGD peptide (100 nmoles; D) Images were captured on the Pearl® Imager; 800 nm signal is presented in pseudo-color overlaid on a white light image of the mouse. The images are normalized to the same look-up-table.
A) 基于 On-Cell Western 细胞的测定用于评估 IRDye 800CW RGD 与 U87（胶质母细胞瘤）和 22Rv1（前列腺癌）肿瘤细胞系的结合亲和力。 B) IRDye 800CW RGD 肽的结合被未标记的 RGD 阻断，但未被 U87 肿瘤细胞中的非特异性 RAD 肽阻断。 在预注射 1 小时后静脉注射 IRDye 800CW RGD（1 nmole；C）或 IRDye 800CW RGD（1 nmole）后 24 小时对带有皮下肿瘤 U87（左髋）和 A431（右髋）的裸鼠进行成像 在注射未标记的 RGD 肽之前（100 nmoles；D）在 Pearl® Imager 上捕获图像； 800 nm 信号以覆盖在鼠标白光图像上的伪彩色呈现。 图像被标准化为相同的查找表。

Reference

  1. Huang, R., Vider, J., Kovar, J. L., Olive, D. M., Mellinghoff, I. K., Mayer-Kuckuk, P., … Blasberg, R. G. (2012). Integrin αvβ3-targeted IRDye 800CW near-infrared imaging of glioblastoma. Clinical Cancer Research, 18(20), 5731–5740. doi: 10.1158/1078-0432.CCR-12-0374.

发表评论